TITLE

Firm tried to block report on failure of AIDS vaccine

AUTHOR(S)
Gottlieb, Scott
PUB. DATE
November 2000
SOURCE
BMJ: British Medical Journal (International Edition);11/11/2000, Vol. 321 Issue 7270, p1173
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the objection of biotechnology company Immune Response to the publication of clinical trial results which illustrate the ineffectiveness of the company's experimental AIDS treatment. Conclusion of researchers that the Remune vaccine failed to exhibit any health benefits for AIDS patients; Difficulties involved in the publication of commercial product studies with neutral or negative results.
ACCESSION #
3748886

 

Related Articles

  • Knee-jerk response.  // Nature Biotechnology;Dec2000, Vol. 18 Issue 12, p1223 

    Reports on issues related to the dispute between Carlsbad, California-based Immune Response Corp. and academic researchers over the publication of unfavorable clinical trial data on the company's anti-HIV vaccine Remune. Allegations of the researchers against the company; Explanation given by...

  • Company, academics argue over data. Niiler, Eric // Nature Biotechnology;Dec2000, Vol. 18 Issue 12, p1235 

    Reports that Carlsbad, California-based Immune Response Corp. has started arbitration proceedings against medical researchers at San Francisco, California-based University of California and Cambridge, Massachusetts-based Harvard University over publication of negative data clinical trial of the...

  • Immune Response Pins Hopes on Study Results. Webb, Marion // San Diego Business Journal;9/10/2001, Vol. 22 Issue 37, p1 

    Reports on the filing for regulatory approval of the experimental vaccine drug Remune by Immune Response Corp. in Europe and the United States. Merits of the drug based on the result of Phase II trial; Ability of the drug to reduce the amount of HIV in the bloodstream; Cost projected on the...

  • New Remune data analysis. Niiler, Eric // Nature Biotechnology;Jun2001, Vol. 19 Issue 6, p499 

    Reports on claims of the biotechnology company Immune Response Corp. about the effectiveness of its experimental AIDS vaccine Remune. Details on the data analysis of the vaccine; Disagreement regarding the effectiveness of the vaccine.

  • Clinical trials launched of Salk AIDS vaccine. M.W. // Nature;3/21/1996, Vol. 380 Issue 6571, p190 

    Relates that the Immune Response Corporation in California announced in March 1996 that it has launched a phase-3 trial of the controversial therapeutic AIDS vaccine Remune. An inactivated version of the AIDS virus as the basis of the vaccine; Food and Drug Administration approval for the...

  • Immune Corp reports positive trends early in HIV trial.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p8 

    Reports that Immune Response Corp. has presented encouraging preliminary data from an ongoing Italian phase II study of Remune treatment in HIV positive patients. Observation of positive trends in key markers believed to indicate immune responses against HIV disease; Stabilization of CD4+ T-cell...

  • IRC initiates preclinical development program for HIV vaccine candidate.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p6 

    Reports that the Immune Response Corp. has initiated a preclinical development program with IR103, a new vaccine candidate for the prevention and treatment of HIV. Presentation of the clinical study of IR103; Potentiality of IR103 to prevent and treat HIV; Effect of IR103 on immune response.

  • AIDS Vaccine Researchers Report Having Initial Success. Webb, Marion // San Diego Business Journal;07/17/2000, Vol. 21 Issue 29, p8 

    Reports that San Diego, California-based biotechnology firms Immune Response Corp. and Hollis-Eden Pharmaceuticals Inc. are developing vaccines designed to restore the damaged immune systems of HIV-infected patients. Presentation of study results at the July 2000 International AIDS Conference...

  • AIDS virus continues to mystify researchers. Webb // San Diego Business Journal;3/1/99, Vol. 20 Issue 8, p5 

    Reports on the stonewalling of efforts by two biotechnology companies in San Diego, California to develop a vaccine for acquired immunodeficiency syndrome (AIDS). Type of virus that can change structure; Research efforts of Immune Response Corp. and Cytel Corp.; Absence of perfect animal model...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics